MeSH D000077216 - ovarian epithelial carcinoma
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
D000077216:
Ovarian epithelial carcinoma
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| Immunogen | Mirvetuximab soravtansine | Elahere | 2022-11-14 |
Clinical Trials
Historical Success Rate
Phase 1
63%48/76
Phase 2
21%17/82
Phase 3
0%0/27
Approved: 0Overall Success rate: 0%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use